Another study found that nucleotide-binding oligomerization domain 2 (NOD2), an innate immune sensor that elicits a strong immune response against pathogens, significantly enhances the sensitivity of HCC cells to various therapeutic agents, including lenvatinib, through the AMPK signaling pathway [210]. The gene discussed is NOD2; the disease is hepatocellular carcinoma.